Yes, Entyvio Treats Both Crohn's Disease and Ulcerative Colitis
Entyvio (vedolizumab) is FDA-approved for moderate to severe active ulcerative colitis (UC) in adults and pediatric patients 8 years and older who have had an inadequate response, lost response, or intolerance to conventional therapy or tumor necrosis factor (TNF) blockers.[1] It also carries approval for moderate to severe active Crohn's disease (CD) in adults with similar inadequate responses to conventional therapy or TNF blockers.[1]
How Entyvio Works for These Conditions
Vedolizumab is a monoclonal antibody that selectively blocks the alpha4beta7 integrin, inhibiting gut-specific lymphocyte trafficking without broadly suppressing the immune system.[2] This mechanism addresses the chronic inflammation driving both UC (primarily colon) and CD (anywhere in the GI tract), leading to clinical remission and mucosal healing in responsive patients.[1][2]
Dosing and Administration Differences
For both UC and CD, Entyvio starts with 300 mg IV infusions at weeks 0, 2, and 6, then every 8 weeks.[1] A subcutaneous formulation (Entyvio Pen) is approved for maintenance in UC patients achieving response after IV induction; CD subcutaneous maintenance is under review.[1]
Effectiveness Data from Clinical Trials
In the GEMINI trials, 47% of UC patients achieved clinical response at week 6 (vs. 26% placebo), with sustained remission rates up to 42% at week 52.[2] For CD, GEMINI 2 and 3 showed 39% clinical remission at week 6 (vs. 22% placebo) and durable benefits through week 52.[2] Real-world studies confirm similar efficacy across both diseases, though CD response rates can vary by disease location.[3]
Common Side Concerns and Risks
Patients on Entyvio report similar side effects for UC and CD: upper respiratory infections (13%), nasopharyngitis (13%), headache (12%), and infusion reactions (4%).[1] PML risk exists due to progressive multifocal leukoencephalopathy (rare, <0.1%), and live vaccines are contraindicated.[1] No major differences in safety profiles between UC and CD use.
When to Consider Alternatives
Entyvio serves as a gut-selective option when TNF inhibitors like Humira or Inflectra fail, or for patients preferring lower systemic immunosuppression risk over JAK inhibitors (Xeljanz) or IL-23 blockers (Skyrizi).[3] It's not first-line but fits after aminosalicylates or steroids.
Sources
[1]: Entyvio Prescribing Information (FDA)
[2]: New England Journal of Medicine - GEMINI Trials
[3]: Clinical Gastroenterology and Hepatology - Real-World Vedolizumab Outcomes